• Vaccine Name: HSP90-ESAT-6-HspX-RipA
• Target Pathogen: Mycobacterium tuberculosis
• Target Disease: Tuberculosis
• Type: Subunit vaccine
• Status: Research
• Host Species for Licensed Use: Mouse
• Antigen: The antigen is composed of HSP90, ESAT-6, HspX and RipA Mycobacterium tuberculosis antigens(Kwon et al., 2024).
• EsxA (ESAT-6) gene engineering:
  • Type: Fusion Protein
  • Description: Use in fusion protein preparation(Kwon et al., 2024).
  • Detailed Gene Information: Click Here.
• hspX gene engineering:
  • Type: Fusion Protein
  • Description: Use in preparing fusion protein(Kwon et al., 2024).
  • Detailed Gene Information: Click Here.
• ripA gene engineering:
  • Type: Fusion Protein
  • Description: Use in fusion protein preparation(Kwon et al., 2024).
  • Detailed Gene Information: Click Here.
• htpG gene engineering:
  • Type: Fusion Protein
  • Description: Use in fusion protein preparation(Kwon et al., 2024).
  • Detailed Gene Information: Click Here.
• Preparation: The HEHR fusion gene was constructed by sequential PCR and overlap-extension cloning of HSP90-ESAT-6 with HspX-RipA, inserted into the pET22b vector, expressed recombinantly, purified, and formulated with lyophilized CIA09A prior to immunization; a tag-free version of HEHR was also produced for validation(Kwon et al., 2024).
• Immunization Route: subcutaneous injection

Mouse Response

• Host Strain: C57BL/6
• Host age: 6 to 7 weeks old
• Host gender: Female
• Vaccination Protocol: Mice were primed subcutaneously with BCG, followed by three booster immunizations with HEHR/CIA09A administered subcutaneously or intramuscularly at 3-week intervals, and subsequently challenged with M. tuberculosis(Kwon et al., 2024).
• Immune Response: BCG-primed HEHR/CIA09A boosting induced robust antigen-specific multifunctional CD4? T-cells producing IFN-?, IL-17A, TNF-?, and IL-2, with increased CXCR3?KLRG1? effector phenotypes in the lung, indicating durable Th1/Th17 immunity(Kwon et al., 2024).
• Challenge Protocol: Four weeks after the final booster, mice were aerosol-challenged with hypervirulent Mycobacterium tuberculosis Haarlem strain M2 (~200 CFU) and analyzed 12 weeks post-infection(Kwon et al., 2024).
• Efficacy: BCG-primed HEHR/CIA09A boosting significantly reduced lung and spleen bacterial burden and pulmonary inflammation, providing superior and long-lasting protection compared to BCG alone or earlier subunit vaccines(Kwon et al., 2024).
• Information about this animal model: Mouse Model for TB research